Yes, Belsomra Treats Insomnia
Belsomra (suvorexant) is an FDA-approved prescription medication for adults with insomnia, specifically to help people fall asleep faster and stay asleep longer. It targets orexin receptors in the brain, which regulate wakefulness, unlike traditional sedatives that broadly suppress the central nervous system.[1]
How Does Belsomra Work?
Belsomra blocks orexin-A and orexin-B, chemicals that promote alertness. Taken 30 minutes before bed, it reduces wake signals without causing next-day grogginess in most users at standard doses (5-20 mg). Clinical trials showed it cut time to fall asleep by 10-20 minutes and increased total sleep time by 20-40 minutes compared to placebo.[2]
Who Can Take Belsomra and When?
Prescribed for chronic insomnia where sleep troubles occur at least three nights a week for three months. Not for naps, shift workers, or those with narcolepsy. Avoid if you have severe liver issues, use strong CYP3A inhibitors (like ketoconazole), or drink alcohol that night. Start at 5 mg for women and those over 65 due to slower metabolism.[1][3]
Common Side Effects and Risks
Daytime sleepiness affects 5-10% of users, with risks of sleep paralysis, hallucinations, or complex behaviors like sleep-driving (0.2-1% incidence). Black box warning for these behaviors. Long-term use data shows no major tolerance buildup, but monitor for depression or suicidal thoughts.[3]
How Does It Compare to Ambien or Lunesta?
| Drug | Class | Onset | Half-Life | Key Difference |
|------|--------|--------|-----------|---------------|
| Belsomra | Orexin antagonist | 30 min | 12 hrs | Targets wakefulness; less cognitive impairment |
| Ambien (zolpidem) | Non-benzodiazepine | 15-30 min | 2-3 hrs | Faster acting; higher abuse potential |
| Lunesta (eszopiclone) | Non-benzodiazepine | 30 min | 6 hrs | Builds tolerance quicker; bitter taste |
Belsomra has lower dependence risk but costs more ($400-500/month without insurance).[4]
Patent Status and Availability
Suvorexant patent expires in 2029 in the US, with pediatric exclusivity to 2030. No generics yet; Merck holds exclusivity. Check DrugPatentWatch.com for updates on challenges or ANDA filings.[5]
Sources
[1] FDA Label for Belsomra
[2] NEJM Trial on Suvorexant
[3] Belsomra Prescribing Information
[4] GoodRx Pricing Comparison
[5] [DrugPatentWatch: Suvorexant](https://www.drugpatentwatch.com/p/tradename/BEL SOMRA)